Global BRICS Diabetes Treatment and Prevention Market Research Report By Type (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), By Treatment Method (Insulin Therapy, Oral Medications, Dietary Management, Physical Activity, Monitoring Devices), By Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacy, Specialty Clinics), By End User (Individuals, Healthcare Providers, Research Institutions) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035
As per Market Research Future analysis, the BRICS Diabetes Treatment and Prevention Market was estimated at 7.35 USD Billion in 2024. The market is projected to grow from 7.707 USD Billion in 2025 to 12.39 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 4.86% during the forecast period 2025 - 2035
The BRICS Diabetes Treatment and Prevention Market is poised for substantial growth driven by innovative treatment approaches and increasing healthcare investments.
| 2024 Market Size | 7.35 (USD Billion) |
| 2035 Market Size | 12.39 (USD Billion) |
| CAGR (2025 - 2035) | 4.86% |
Novo Nordisk (DK), Sanofi (FR), Boehringer Ingelheim (DE), Bristol-Myers Squibb (US), Merck & Co. (US), AstraZeneca (GB), GlaxoSmithKline (GB), Lilly (US), Abbott (US)
Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry
The BRICS Diabetes Treatment and Prevention Market is currently experiencing a dynamic evolution, driven by a confluence of factors that include rising prevalence rates of diabetes, increasing awareness regarding the disease, and advancements in treatment modalities. The market appears to be characterized by a growing emphasis on personalized medicine, which suggests a shift towards tailored therapeutic approaches that cater to individual patient needs. Furthermore, the integration of technology in diabetes management, such as mobile health applications and telemedicine, seems to enhance patient engagement and adherence to treatment regimens. This trend indicates a potential transformation in how diabetes care is delivered across the BRICS nations. Moreover, the market landscape is likely influenced by collaborative efforts among governments, healthcare providers, and pharmaceutical companies to improve access to diabetes care. Initiatives aimed at education and prevention may play a crucial role in curbing the rising incidence of diabetes within these regions. As the BRICS Diabetes Treatment and Prevention Market continues to evolve, it may reflect broader global trends in healthcare, emphasizing the importance of preventive strategies alongside effective treatment options. The interplay of these factors suggests a complex yet promising future for diabetes management in these emerging economies.
The BRICS Diabetes Treatment and Prevention Market is witnessing a notable shift towards personalized treatment strategies. This trend indicates a growing recognition of the need for individualized care plans that consider the unique characteristics of each patient, including genetic factors, lifestyle, and comorbidities. Such tailored approaches may enhance treatment efficacy and improve patient outcomes.
The integration of technology into diabetes management is becoming increasingly prevalent within the BRICS Diabetes Treatment and Prevention Market. Innovations such as mobile health applications, continuous glucose monitoring systems, and telehealth services appear to facilitate better patient engagement and adherence to treatment protocols, potentially leading to improved health outcomes.
Collaborative initiatives among various stakeholders, including governments, healthcare providers, and pharmaceutical companies, are emerging as a key trend in the BRICS Diabetes Treatment and Prevention Market. These partnerships may focus on enhancing access to care, promoting education, and implementing preventive measures, thereby addressing the growing diabetes burden in these regions.
The increase in healthcare expenditure across BRICS nations is a significant driver of the BRICS Diabetes Treatment and Prevention Market. As economies grow, governments and private sectors are allocating more resources to healthcare, particularly in the realm of chronic disease management. Reports indicate that healthcare spending in BRICS countries is expected to rise by over 5% annually, reflecting a commitment to improving health services. This financial investment is likely to enhance the availability of diabetes treatments, medications, and preventive programs. Additionally, increased funding for research and development in diabetes care is anticipated to yield innovative solutions, further propelling the market. Consequently, the BRICS Diabetes Treatment and Prevention Market stands to gain from this upward trend in healthcare expenditure.
The increasing prevalence of diabetes within the BRICS Diabetes Treatment and Prevention Market is a critical driver. As lifestyle changes and urbanization continue to influence dietary habits, the number of individuals diagnosed with diabetes is on the rise. Reports indicate that the prevalence of diabetes in BRICS nations is projected to reach approximately 150 million by 2030. This alarming trend necessitates the development and implementation of effective treatment and prevention strategies, thereby propelling the market forward. Healthcare systems are increasingly focusing on diabetes management, leading to a surge in demand for innovative therapies and preventive measures. Consequently, the BRICS Diabetes Treatment and Prevention Market is likely to experience substantial growth as stakeholders respond to this pressing health challenge.
The rising awareness and education surrounding diabetes are crucial drivers for the BRICS Diabetes Treatment and Prevention Market. As public knowledge about diabetes and its complications increases, individuals are more likely to seek preventive care and treatment options. Educational programs aimed at both healthcare professionals and the general public are being implemented across BRICS nations, emphasizing the importance of lifestyle modifications and regular health screenings. This heightened awareness is expected to lead to an increase in early diagnosis and treatment adherence, ultimately improving health outcomes. Furthermore, as patients become more informed about their condition, they are likely to engage more actively in their treatment plans, thereby fostering a more robust market for diabetes management solutions within the BRICS Diabetes Treatment and Prevention Market.
Technological advancements play a significant role in the evolution of the BRICS Diabetes Treatment and Prevention Market. Innovations such as continuous glucose monitoring systems, insulin pumps, and telemedicine solutions are transforming diabetes management. The integration of artificial intelligence and machine learning into treatment protocols is enhancing personalized care, allowing for more effective monitoring and intervention strategies. Market data suggests that the diabetes technology market is expected to grow at a compound annual growth rate of over 10% in the coming years. This growth is indicative of the increasing reliance on technology to improve patient outcomes and streamline healthcare processes. As a result, the BRICS Diabetes Treatment and Prevention Market is likely to benefit from these advancements, leading to improved treatment options and patient engagement.
Government initiatives aimed at combating diabetes are pivotal in shaping the BRICS Diabetes Treatment and Prevention Market. Various BRICS nations have introduced policies to enhance awareness, improve access to healthcare, and promote preventive measures. For instance, initiatives that focus on public health campaigns and subsidized medications are becoming more prevalent. These efforts are designed to reduce the economic burden of diabetes, which is estimated to cost BRICS countries billions annually. Furthermore, the establishment of national diabetes registries and screening programs is likely to facilitate early diagnosis and treatment, thereby fostering a more proactive approach to diabetes management. Such governmental support is expected to stimulate growth within the BRICS Diabetes Treatment and Prevention Market.
In the BRICS Diabetes Treatment and Prevention Market, Type 2 Diabetes holds a significant share, representing the largest segment due to its higher prevalence in the population. This segment accounts for the majority of diabetes cases, attributed to factors like sedentary lifestyles and unhealthy dietary habits prevalent in these regions. Type 1 Diabetes and Gestational Diabetes follow, catering to smaller demographic niches but are vital in holistic market dynamics.
Growth trends indicate that Type 1 Diabetes is emerging as the fastest-growing segment, spurred by increasing awareness and advances in treatment methodologies. This rise is largely influenced by improved diagnosis rates and the growing focus on personalized medicine. Moreover, the demographic shifts and urbanization in BRICS nations are further driving the expansion of diabetes management options, particularly for Type 1 Diabetes, making it a segment to watch closely in the coming years.
Type 2 Diabetes (Dominant) vs. Gestational Diabetes (Emerging)
Type 2 Diabetes remains the dominant force in the BRICS Diabetes Treatment and Prevention Market, largely due to the growing prevalence among adults and the aging population. With lifestyle factors contributing heavily to its surge, Type 2 Diabetes management incorporates a range of therapeutic approaches, from oral medications to lifestyle adjustments. Conversely, Gestational Diabetes is recognized as an emerging segment, gaining attention due to rising awareness and the impact of maternal health on long-term health outcomes for both mothers and infants. Healthcare providers are increasingly prioritizing the management of gestational diabetes, leading to the development of specialized prenatal care programs and dietary counseling, positioning it as a key area for growth within the diabetes care market.
In the BRICS Diabetes Treatment and Prevention Market, Insulin Therapy holds the largest market share as it remains a critical component in diabetes management among patients dependent on insulin. Oral Medications are rapidly gaining traction due to their convenience and increasing acceptance among prescribers and patients alike, thus proving to be a formidable segment under the broader treatment methodology. Dietary Management and Physical Activity also play significant roles, though they cater typically to lifestyle adjustments rather than medical interventions, while Monitoring Devices carve a niche for themselves by facilitating effective disease management through technology integration. Growth trends indicate a shifting paradigm in diabetes management strategies among the BRICS nations. The inclination towards Oral Medications is fuelled by advancements in drug formulations and increased awareness regarding diabetes management options. Similarly, the rise in health-consciousness is pushing patients toward Dietary Management and Physical Activities, as these are recognized as essential pillars in preventing and managing diabetes, further supported by government initiatives promoting healthier lifestyles.
Insulin Therapy (Dominant) vs. Monitoring Devices (Emerging)
Insulin Therapy is the cornerstone of diabetes management, particularly for Type 1 diabetes patients. It is esteemed for its ability to quickly regulate blood glucose levels, ensuring patient safety and improving quality of life. This treatment's dominance is enhanced by its long-established medical protocols and effectiveness. On the flip side, Monitoring Devices represent an emerging trend, specifically with innovations in continuous glucose monitoring technologies. These devices offer real-time glucose tracking, enabling patients to manage their conditions with more autonomy and better data-driven decision-making. As healthcare technology continues to evolve, the role of Monitoring Devices is set to gain prominence, providing a complement to traditional insulin treatments by enhancing engagement in self-care among diabetic patients.
The BRICS Diabetes Treatment and Prevention Market showcases a diverse landscape of distribution channels, with hospitals commanding the largest share. They serve as primary care hubs, where individuals receive comprehensive diabetes management services, ensuring a significant focus on in-patient and outpatient treatments. Retail pharmacies also play an essential role in dispensing medications, but their market share is gradually being complemented by the rise of online pharmacies, particularly among tech-savvy consumers seeking convenience and accessibility.
The trends shaping this segment are driven by the increasing prevalence of diabetes and the need for effective treatment and prevention solutions. Online pharmacies are rapidly gaining traction, propelled by the growing trend of digital health services, where patients are looking for easy access to medications without visiting a physical store. Additionally, specialty clinics are focusing on tailored treatment regimens, which are enhancing their presence within the distribution channel, appealing to patients seeking specialized care for diabetes management.
Hospitals (Dominant) vs. Online Pharmacy (Emerging)
In the BRICS market, hospitals remain a dominant force in the distribution of diabetes treatment and prevention solutions. They are equipped with specialized healthcare teams and infrastructure, ensuring holistic management and follow-ups for diabetes patients. Conversely, online pharmacies are an emerging channel, catering to a growing audience that is favoring the convenience of home delivery and access to diverse products. With an increasing digital literacy among the population and strategies that focus on online consultations, these pharmacies are challenging traditional delivery methods. Specialty clinics are also increasing, offering personalized care plans and contributing further to the competitive landscape of diabetes treatment distribution, creating a nuanced dynamic within the overall market.
In the BRICS Diabetes Treatment and Prevention Market, the distribution of market share among end users reveals that Individuals constitute the largest segment. This significant share is attributed to the growing prevalence of diabetes across the BRICS nations, driving demand for personalized treatment and management solutions. Meanwhile, Healthcare Providers are witnessing rapid growth as more stakeholders, including hospitals and clinics, are recognizing the need for comprehensive care solutions, contributing to a robust shift toward collaboration between pharmaceutical companies and healthcare institutions.
As the number of diabetes cases continues to rise, there is an increasing emphasis on preventive measures and the importance of education and resources for those affected. This focus has spurred investment in research and development tailored to Individuals and Healthcare Providers alike. Additionally, the integration of technology in healthcare delivery is enhancing the reach and effectiveness of treatments, thus accelerating the growth of healthcare provider engagement in diabetes management, enabling better patient outcomes.
Individuals (Dominant) vs. Healthcare Providers (Emerging)
Individuals in the BRICS Diabetes Treatment and Prevention Market are recognized as the dominant force, as they directly utilize various treatment methods and products for managing diabetes. This segment encompasses a diverse population affected by diabetes, which drives demand for personalized interventions, lifestyle management resources, and educational materials. On the other hand, Healthcare Providers are identified as an emerging segment, rapidly growing as they adapt to the increasing burden of diabetes. This includes hospitals, clinics, and private practices that ensure patient access to treatment options and preventive strategies. Their role is evolving, emphasizing collaborative approaches with pharmaceutical companies, promoting innovation in diabetes care, and enhancing patient engagement through integrated health solutions.
Get more detailed insights about BRIC Diabetes Treatment Prevention Market Request Free Sample
North America is the largest market for diabetes treatment and prevention, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high disposable incomes, and increasing prevalence of diabetes. Regulatory support from agencies like the FDA accelerates the approval of innovative therapies, driving market growth. The rising awareness of diabetes management and prevention strategies further fuels demand. The United States is the leading country in this market, with significant contributions from Canada. Major players such as Novo Nordisk, Sanofi, and Merck & Co. dominate the landscape, offering a range of products from insulin to oral medications. The competitive environment is characterized by continuous innovation and strategic partnerships, ensuring a robust supply of diabetes care solutions.
Europe is the second-largest market for diabetes treatment, accounting for approximately 30% of the global share. The region's growth is driven by supportive healthcare policies, increasing diabetes prevalence, and a strong emphasis on preventive care. The European Medicines Agency (EMA) plays a crucial role in regulating and approving new treatments, fostering innovation in diabetes management. The rising focus on personalized medicine and digital health solutions is also contributing to market expansion. Leading countries in this region include Germany, France, and the UK, where key players like Boehringer Ingelheim and AstraZeneca are actively involved. The competitive landscape is marked by collaborations between pharmaceutical companies and healthcare providers, enhancing the availability of advanced treatment options. The presence of robust healthcare systems ensures that patients have access to the latest therapies and technologies.
Asia-Pacific is witnessing rapid growth in the diabetes treatment market, holding approximately 20% of the global share. The region's growth is fueled by rising urbanization, changing lifestyles, and increasing obesity rates, leading to a higher prevalence of diabetes. Governments are implementing initiatives to improve healthcare access and promote diabetes awareness, which are critical for market expansion. Regulatory bodies are also focusing on streamlining approval processes for new treatments, enhancing market dynamics. China and India are the leading countries in this market, with significant contributions from Japan and Australia. The competitive landscape features both multinational corporations and local players, ensuring a diverse range of treatment options. Key players like Lilly and Abbott are expanding their presence, focusing on innovative solutions tailored to the unique needs of the region's population. The growing emphasis on preventive care is also shaping the market landscape.
The Middle East and Africa region is emerging as a significant market for diabetes treatment, holding about 5% of the global share. The growth is driven by increasing diabetes prevalence, urbanization, and rising healthcare investments. Governments are prioritizing diabetes management in their health agendas, leading to improved access to treatment and preventive measures. Regulatory frameworks are evolving to support the introduction of new therapies, which is crucial for market development. Countries like South Africa and the UAE are at the forefront of this market, with a growing number of healthcare facilities and initiatives aimed at diabetes care. The competitive landscape includes both international and local players, with companies like GlaxoSmithKline and Sanofi actively participating. The focus on education and awareness campaigns is also vital in addressing the diabetes epidemic in this region, ensuring that patients receive timely and effective care.
The Global BRICS Diabetes Treatment and Prevention Market has gained considerable attention due to the rising prevalence of diabetes across the member countries of BRICS, which includes Brazil, Russia, India, China, and South Africa.The market landscape is characterized by intense competition among healthcare companies striving to offer innovative treatment solutions and preventive measures for diabetes. The increasing investment in healthcare infrastructure, coupled with a growing awareness of diabetes management among patients, is driving the competition further.Companies are focusing on research and development to create effective medications, lifestyle interventions, and technologies such as diabetes management software and devices. The rise of digital health platforms has also transformed the way care is delivered, adding another layer of competition within the market.As the healthcare needs in these emerging economies continue to evolve, players in the diabetes treatment and prevention landscape must adapt quickly to capture market share and meet the demands of their patients.Merck and Co has established itself as a formidable player in the Global BRICS Diabetes Treatment and Prevention Market. The company's strong portfolio of diabetes medications, particularly those aimed at managing both Type 1 and Type 2 diabetes, positions it favorably within this competitive landscape.Merck's commitment to research and development is evident in its ongoing efforts to innovate and improve diabetes treatments, enhancing the company's reputation as a leader in the field. The firm's extensive global reach allows it to leverage its resources effectively, tapping into diverse markets while navigating regulatory landscapes with ease.Additionally, Merck's robust collaborations with healthcare providers, advocacy groups, and academic institutions further bolster its market presence and strengthen its position as a trusted partner in diabetes care. The company's established brand recognition and unwavering focus on improving patient outcomes underpin its competitive edge in the Global BRICS arena.Pfizer is another key contender in the Global BRICS Diabetes Treatment and Prevention Market, known for its diversified product offerings and strong market presence. The company's portfolio includes several essential medications designed to manage diabetes effectively, as well as complementary products that assist in broader patient health management.Pfizer's commitment to innovation is demonstrated through ongoing research initiatives aimed at discovering new formulations and treatment options that address the complexities associated with diabetes.Moreover, the company's strategic mergers and acquisitions have strengthened its capabilities in this market, allowing it to integrate new technologies and enhance its service offerings. This has not only expanded Pfizer’s reach but also solidified its competitive position in the market.By fostering partnerships with healthcare systems and leveraging digital health solutions, Pfizer continues to adapt to the evolving landscape of diabetes care, ensuring that it remains at the forefront of treatment developments in the Global space.
The Global BRICS Diabetes Treatment and Prevention Market has seen significant developments in recent months, particularly with key players like Merck and Co, Pfizer, AbbVie, Novo Nordisk, Eli Lilly, and Johnson and Johnson actively enhancing their diabetes management protocols. Novo Nordisk recently received regulatory approval for a new insulin product in September 2023, indicating ongoing innovation in the sector.
In August 2023, Merck and Co announced a collaboration with Amgen to expand diabetes treatment options, focusing on integrated care solutions. As for mergers, there are reports of Johnson and Johnson's acquisition of a small biotech firm specializing in diabetes technologies in July 2023, which positions them to broaden their market share.
Over the last two years, the Global BRICS market has experienced growth in valuation, largely driven by an increasing prevalence of diabetes and rising healthcare expenditures. According to industry reports, the demand for effective diabetes management strategies continues to escalate, prompting pharmaceutical companies to invest heavily in Research and Development initiatives to provide innovative solutions.
With countries in the BRICS working on improving healthcare access, the market is geared for further growth and dynamic advancements.
The BRICS Diabetes Treatment and Prevention Market is projected to grow at a 4.86% CAGR from 2025 to 2035, driven by increasing prevalence, technological advancements, and enhanced healthcare access.
New opportunities lie in:
By 2035, the market is expected to be robust, reflecting substantial growth and innovation.
| MARKET SIZE 2024 | 7.35(USD Billion) |
| MARKET SIZE 2025 | 7.707(USD Billion) |
| MARKET SIZE 2035 | 12.39(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.86% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Novo Nordisk (DK), Sanofi (FR), Boehringer Ingelheim (DE), Bristol-Myers Squibb (US), Merck & Co. (US), AstraZeneca (GB), GlaxoSmithKline (GB), Lilly (US), Abbott (US) |
| Segments Covered | Type, Treatment Method, Distribution Channel, End User, Regional |
| Key Market Opportunities | Integration of digital health technologies enhances diabetes management in the BRICS Diabetes Treatment and Prevention Market. |
| Key Market Dynamics | Rising prevalence of diabetes drives innovation in treatment and prevention strategies across BRICS nations. |
| Countries Covered | North America, Europe, APAC, South America, MEA |
The market valuation was 7.35 USD Billion in 2024.
The projected valuation for 2035 is 12.39 USD Billion.
The expected CAGR during the forecast period is 4.86%.
Key players include Novo Nordisk, Sanofi, Boehringer Ingelheim, and others.
The Type 2 Diabetes segment was valued at 4.12 USD Billion in 2024 and is projected to reach 6.89 USD Billion.
Insulin Therapy was valued at 1.5 USD Billion in 2024 and is expected to grow to 2.5 USD Billion.
Hospitals had the highest valuation at 2.21 USD Billion in 2024.
Dietary Management was valued at 1.2 USD Billion in 2024 and is projected to reach 2.0 USD Billion.
The Individuals segment is projected to grow from 3.0 USD Billion in 2024 to 5.0 USD Billion by 2035.
Gestational Diabetes was valued at 1.76 USD Billion in 2024 and is expected to reach 3.05 USD Billion.
Kindly complete the form below to receive a free sample of this Report
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
“Thank you, this will be very helpful for OQS.”
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”
